Discovery of 5-(1-benzyl-1H-imidazol-4-yl)-1,2,4-oxadiazole derivatives as novel RIPK1 inhibitors via structure-based virtual screening

被引：0

作者：

Yu, Yanzhen ^{[1
]}

Hu, Yunzhen ^{[2
]}

Yan, Huihui ^{[1
]}

Zeng, Xin ^{[1
]}

Yang, Haodong ^{[3
]}

Xu, Lei ^{[4
]}

Sheng, Rong ^{[1
,3
]}

机构：

[1] Zhejiang Univ, Coll Pharmaceut Sci, Hangzhou 310058, Peoples R China

[2] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Clin Pharm, Hangzhou, Peoples R China

[3] Zhejiang Univ, Jinhua Inst, Jinhua, Peoples R China

[4] Jiangsu Univ Technol, Inst Bioinformat & Med Engn, Sch Elect & Informat Engn, Changzhou, Peoples R China

来源：

DRUG DEVELOPMENT RESEARCH | 2024年 / 85卷 / 05期

关键词：

molecular dynamics; RIPK1; inhibitors; virtual screening; INTERACTING PROTEIN-1 RIP1; HIGHLY POTENT; CELL-DEATH; KINASE; PHOSPHORYLATION; IDENTIFICATION;

D O I：

10.1002/ddr.22235

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

RIPK1 plays a key role in necroptosis and is associated with various inflammatory diseases. Using structure-based virtual screening, a novel hit with 5-(1-benzyl-1H-imidazol-4-yl)-1,2,4-oxadiazole scaffold was identified as an RIPK1 inhibitor with an IC50 value of 1.3 mu M. Further structure-activity relationship study was performed based on similarity research and biological evaluation. The molecular dynamics simulation of compound 2 with RIPK1 indicated that it may act as a type II kinase inhibitor. This study provides a highly efficient way to discover novel scaffold RIPK1 inhibitors for further development.

引用

页数：11

共 50 条

[1] 2-(1-benzyl-5-methyl-1H-imidazol-4-yl)-1,3,4-oxadiazole
Li, Jing
ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS, 2007, 63 : O2976 - U2993
[2] 2-(1-benzyl-4-methyl-1H-imidazol-5-yl)1,3,4-oxadiazole
Li, Jing
Zhou, Hong-Bin
ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS, 2007, 63 : O2977 - U3002
[3] Novel 1,2,4-Oxadiazole Derivatives in Drug Discovery
Biernacki, Karol
Dasko, Mateusz
Ciupak, Olga
Kubinski, Konrad
Rachon, Janusz
Demkowicz, Sebastian
PHARMACEUTICALS, 2020, 13 (06)
[4] Synthesis and antimicrobial activity of 5-(1H-1,2,3-triazol-4-yl)-1,2,4-oxadiazole derivatives
Konstantin Yu. Krolenko
Sergiy V. Vlasov
Irina A. Zhuravel
Chemistry of Heterocyclic Compounds, 2016, 52 : 823 - 830
[5] Synthesis and antimicrobial activity of 5-(1H-1,2,3-triazol-4-yl)-1,2,4-oxadiazole derivatives
Krolenko, Konstantin Yu.
Vlasov, Sergiy V.
Zhuravel, Irina A.
CHEMISTRY OF HETEROCYCLIC COMPOUNDS, 2016, 52 (10) : 823 - 830
[6] Discovery of novel sphingosine kinase 1 inhibitors via structure-based hierarchical virtual screening
Wang, Xiaojian
Sun, Chenbin
Fang, Liang
Yin, Dali
MEDCHEMCOMM, 2015, 6 (03) : 413 - 417
[7] 3-(3,4-Dichlorophenyl)-5-(1H-indol-5-yl)-1,2,4-oxadiazole
Efimova, Julia A.
Shetnev, Anton A.
Baykov, Sergey V.
Petzer, Anel
Petzer, Jacobus P.
MOLBANK, 2023, 2023 (01)
[8] Facial synthesis of novel 3-(2-methylbenzofuran-3-yl)-5-((4-(phenoxymethyl)-1H-1,2,3-triazole-1-yl)methyl)-1,2,4-oxadiazole derivatives
Anterbedy, Jagram
Mokenapelli, Sudhakar
Thalari, Gangadhar
SYNTHETIC COMMUNICATIONS, 2021, 51 (09) : 1417 - 1424
[9] Discovery of novel N-(1-benzyl-1H-imidazol-2-yl)amide derivatives as melanocortin 1 receptor agonists
Sato, Atsushi
Imashiro, Ritsuo
Tsujishima, Hidekazu
Tanimoto, Kouichi
Miyashiro, Masahiko
Chiba, Hiroaki
Kondo, Masahiro
Yamamoto, Yasuo
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2022, 78
[10] Rational design-aided discovery of novel 1,2,4-oxadiazole derivatives as potential EGFR inhibitors
Unadkat, Vishal
Rohit, Shishir
Parikh, Paranjay
Sanna, Vinod
Singh, Sanjay
BIOORGANIC CHEMISTRY, 2021, 114

← 1 2 3 4 5 →